SEC Form 4 · accession 0001209191-15-015052
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Geert Cauwenbergh
Officer — President & CEO · Director
Period of report
Feb 17, 2015
Accepted (ET)
Feb 18, 2015 · 9:21 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Feb 17, 2015 | P | 4,000 | $1.17 | A | 62,500 | D | |
| Common stock, $0.0001 par value | holding | — | — | — | 5,000 | I | By spouse | |
| Common stock, $0.0001 par valueF1 | holding | — | — | — | 4,500 | I | By child |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares held by the Reporting Person's son. The Reporting Person disclaims beneficial ownership of such shares and this report shall not constitute an admission of beneficial ownership.